Two new mutations in cholangiocarcinoma increase the therapeutic possibilities up to a 70%

A study led by researchers from IDIBAPS and funded by the aecc-Cataluña against Cancer in Barcelona has identified, for the first time, two genetic alterations that occur in intrahepatic cholangiocarcinoma (ICCA) and may represent a therapeutic target. Furthermore, they have mapped all the molecular alterations that occur in this type of liver cancer and they have found that 70% of patients have at least one of them. Dr. Josep M. Llovet, ICREA Research Professor at the HCC Translational Research Lab of the Liver Unit at IDIBAPS and Director of Mount Sinai Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York), and Dra. Daniela Sia, researcher at the same group, are the principal investigator and the first author of the paper published in the journal Nature Communications. Dr. Josep Fuster, from the IDIBAPS Hepatic Oncology team and Surgery Professor has also participated in the study.